Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastrointestinal Cancer Excellence Forum

Gastrointestinal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Nataliya Uboha, MD, PhD, University of Wisconsin
Videos
03/30/2023
At the 2023 Great Debates and Updates in Gastrointestinal Malignancies in Chicago, Nataliya Uboha, MD, PhD, gave an overview of her presentation on biomarkers and targeting treatment for gastroesophageal cancers.
At the 2023 Great Debates and Updates in Gastrointestinal Malignancies in Chicago, Nataliya Uboha, MD, PhD, gave an overview of her presentation on biomarkers and targeting treatment for gastroesophageal cancers.
At the 2023 Great Debates and...
03/30/2023
Oncology
Sebastian Stintzing, MD, Charité — Berlin University of Medicine
Videos
02/08/2023
Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...
Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...
Sebastian Stintzing, MD, shares...
02/08/2023
Oncology
John Strickler, MD, Duke University
Videos
02/02/2023
John Strickler, MD, shares insights on the FDA’s accelerated approval of tucatinib in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer.
John Strickler, MD, shares insights on the FDA’s accelerated approval of tucatinib in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer.
John Strickler, MD, shares...
02/02/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Gary Deng, MD, Memorial Sloan Kettering Cancer Center
Videos
12/20/2022
At the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, Gary Deng, MD, discusses modes of complementary medicine that patients with gastrointestinal cancers may be curious about.
At the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, Gary Deng, MD, discusses modes of complementary medicine that patients with gastrointestinal cancers may be curious about.
At the 2022 Great Debates &...
12/20/2022
Oncology
Quiz
11/30/2022
When should palliative care be initiated in the treatment of a patients with gastrointestinal malignancies?
When should palliative care be initiated in the treatment of a patients with gastrointestinal malignancies?
When should palliative care be...
11/30/2022
Oncology
Rajiv Agarwal, MD, Vanderbilt University, Medical Center
Videos
11/21/2022
Rajiv Agarwal, MD, discusses how to best provide palliative care for patients with gastrointestinal cancers, a topic he presented at the 2022 Great Debates and Updates in Gastrointestinal Malignancies virtual meeting.
Rajiv Agarwal, MD, discusses how to best provide palliative care for patients with gastrointestinal cancers, a topic he presented at the 2022 Great Debates and Updates in Gastrointestinal Malignancies virtual meeting.
Rajiv Agarwal, MD, discusses how...
11/21/2022
Oncology
Ghassan Abou-Alfa, MD, Memorial Sloan Kettering
Videos
11/21/2022
Ghassan Abou-Alfa, MD, shares insights about the recent FDA approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma and discusses findings from the HIMALAYA trial, which led to the approval.
Ghassan Abou-Alfa, MD, shares insights about the recent FDA approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma and discusses findings from the HIMALAYA trial, which led to the approval.
Ghassan Abou-Alfa, MD, shares...
11/21/2022
Oncology
Alvaro Arjona-Sanchez, MD, Hospital Universitario Reina Sofia
Videos
11/14/2022
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Alvaro Arjona-Sanchez, MD,...
11/14/2022
Oncology
Joseph Chao, MD, City of Hope Comprehensive Cancer Center
Videos
09/29/2022
Joseph Chao, MD, reviews his presentation on new and upcoming targeted agents in gastric cancer from the Great Debates and Updates in Gastrointestinal Malignancies virtual meeting in September 2022.
Joseph Chao, MD, reviews his presentation on new and upcoming targeted agents in gastric cancer from the Great Debates and Updates in Gastrointestinal Malignancies virtual meeting in September 2022.
Joseph Chao, MD, reviews his...
09/29/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement